Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601668897> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2601668897 abstract "10032 Background: Therapy for ALL has evolved such that the risk for late effects in children treated in early eras is likely different from those that will occur in children treated today. In order to estimate future risks for late effects in newly diagnosed children with standard risk ALL, we examined the long-term outcomes in a cohort of patients enrolled in the CCSS who were treated in a manner analogous to contemporary ALL therapies. Methods: We assessed outcomes that occurred ≥5 years from diagnosis in survivors of ALL enrolled in the CCSS who were aged 1-9.9 years at diagnosis, treated with 0-120 mg/m 2 of anthracyclines and 0-1000 mg/m 2 of alkylating agents, and no radiotherapy. We compared their risks for death, second malignant neoplasms (SMN), chronic physical health conditions and decreased health status with the general population (death and SMN) and the CCSS sibling cohort (remaining outcomes). Results: 556 survivors were eligible. At last assessment, they were a median of 27.8 years old (range 9.1 to 45.7) and 23.4 years (range 5.0-38.0) from diagnosis. 29/556 (5.2%) died (standardized mortality ratio 3.6, 95% CI 2.4-5.2); 12 of these deaths were due to ALL recurrence. Compared to siblings, the rate ratio for ≥1 chronic condition was 1.4 (95% CI 1.3-1.6), and for a severe/life threatening chronic condition was 1.7 (95% CI 1.3-2.3). Four survivors (0.7%) developed a SMN (standardized incidence ratio 1.7, 95% CI 0.5-4.5), 114 were obese (odds ratio (OR) 1.2, 95% CI 1.0-1.5), and 2 (0.4%) reported a stroke. No survivors reported symptomatic congestive heart failure. The OR for reporting adverse general health was 1.2 (95% CI 0.8-1.8), poor mental health 1.3 (95% CI 1.0-1.8), decreased functional status 2.1 (95% CI 1.4-3.0), and activity limitations 1.4 (95% CI 1.1-1.8). Conclusions: Children treated for standard risk ALL on contemporary protocols are at increased risk for future chronic health conditions and decreased health status. Despite excellent survival after leukemia therapy, such survivors will likely benefit from life-long medical care focused on the long-term risks stemming from their therapy." @default.
- W2601668897 created "2017-04-07" @default.
- W2601668897 creator A5008672006 @default.
- W2601668897 creator A5023058832 @default.
- W2601668897 creator A5033126546 @default.
- W2601668897 creator A5037458498 @default.
- W2601668897 creator A5039048640 @default.
- W2601668897 creator A5044156878 @default.
- W2601668897 creator A5046540436 @default.
- W2601668897 creator A5059262359 @default.
- W2601668897 creator A5063077038 @default.
- W2601668897 creator A5065573166 @default.
- W2601668897 creator A5067443773 @default.
- W2601668897 creator A5078465445 @default.
- W2601668897 creator A5078503070 @default.
- W2601668897 creator A5087384700 @default.
- W2601668897 creator A5089743648 @default.
- W2601668897 date "2013-05-20" @default.
- W2601668897 modified "2023-10-01" @default.
- W2601668897 title "Estimated long-term outcomes in children newly diagnosed with standard risk acute lymphoblastic leukemia (ALL) based on similarly treated members of the childhood cancer survivor study (CCSS) cohort." @default.
- W2601668897 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.10032" @default.
- W2601668897 hasPublicationYear "2013" @default.
- W2601668897 type Work @default.
- W2601668897 sameAs 2601668897 @default.
- W2601668897 citedByCount "0" @default.
- W2601668897 crossrefType "journal-article" @default.
- W2601668897 hasAuthorship W2601668897A5008672006 @default.
- W2601668897 hasAuthorship W2601668897A5023058832 @default.
- W2601668897 hasAuthorship W2601668897A5033126546 @default.
- W2601668897 hasAuthorship W2601668897A5037458498 @default.
- W2601668897 hasAuthorship W2601668897A5039048640 @default.
- W2601668897 hasAuthorship W2601668897A5044156878 @default.
- W2601668897 hasAuthorship W2601668897A5046540436 @default.
- W2601668897 hasAuthorship W2601668897A5059262359 @default.
- W2601668897 hasAuthorship W2601668897A5063077038 @default.
- W2601668897 hasAuthorship W2601668897A5065573166 @default.
- W2601668897 hasAuthorship W2601668897A5067443773 @default.
- W2601668897 hasAuthorship W2601668897A5078465445 @default.
- W2601668897 hasAuthorship W2601668897A5078503070 @default.
- W2601668897 hasAuthorship W2601668897A5087384700 @default.
- W2601668897 hasAuthorship W2601668897A5089743648 @default.
- W2601668897 hasConcept C121608353 @default.
- W2601668897 hasConcept C126322002 @default.
- W2601668897 hasConcept C187212893 @default.
- W2601668897 hasConcept C2778461978 @default.
- W2601668897 hasConcept C2909962599 @default.
- W2601668897 hasConcept C2992894027 @default.
- W2601668897 hasConcept C2993561819 @default.
- W2601668897 hasConcept C71924100 @default.
- W2601668897 hasConcept C72563966 @default.
- W2601668897 hasConceptScore W2601668897C121608353 @default.
- W2601668897 hasConceptScore W2601668897C126322002 @default.
- W2601668897 hasConceptScore W2601668897C187212893 @default.
- W2601668897 hasConceptScore W2601668897C2778461978 @default.
- W2601668897 hasConceptScore W2601668897C2909962599 @default.
- W2601668897 hasConceptScore W2601668897C2992894027 @default.
- W2601668897 hasConceptScore W2601668897C2993561819 @default.
- W2601668897 hasConceptScore W2601668897C71924100 @default.
- W2601668897 hasConceptScore W2601668897C72563966 @default.
- W2601668897 hasLocation W26016688971 @default.
- W2601668897 hasOpenAccess W2601668897 @default.
- W2601668897 hasPrimaryLocation W26016688971 @default.
- W2601668897 isParatext "false" @default.
- W2601668897 isRetracted "false" @default.
- W2601668897 magId "2601668897" @default.
- W2601668897 workType "article" @default.